New sudan virus vaccine enters first human tests

NCT ID NCT07565090

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new vaccine designed to prevent Sudan virus disease, a severe illness similar to Ebola. About 112 healthy adults aged 18-50 will receive either the vaccine or a placebo to check for side effects and measure immune responses. The goal is to see if the vaccine is safe and triggers the body's defenses against the virus.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SUDAN VIRUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever Infections viral hemorrhagic fever viral infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • George Washington University

    RECRUITING

    Washington D.C., District of Columbia, 20037, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Johnson County Clin-Trials

    RECRUITING

    Lenexa, Kansas, 66219, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••